Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma
Status:
Completed
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
Study of Plitidepsin (Aplidin®) to determine the recommended dose (RD) of plitidepsin in
Combination with Bortezomib and Dexamethasone in Patients with Relapsed and/or Refractory
Multiple Myeloma.